Fund managers said Australia?s second-largest pathology group, Healius Limited (ASX:HLS), is vulnerable to being picked off by private equity buyers as it accelerates a strategic review after the departure of chief executive Maxine Jaquet. Ms Jaquet has left the top job, effective immediately, after a collapse in profits and margins. Healius announced that chief financial officer Paul Anderson, a former CEO of Network Ten, will take over, expediting a strategic review of the business and examining potential asset sales.